Argent BioPharma Management
Management criteria checks 4/4
Argent BioPharma's CEO is Roby Zomer, appointed in Feb 2016, has a tenure of 8.58 years. total yearly compensation is A$354.02K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 2.67% of the company’s shares, worth $307.65K. The average tenure of the management team and the board of directors is 2.2 years and 3.7 years respectively.
Key information
Roby Zomer
Chief executive officer
AU$354.0k
Total compensation
CEO salary percentage | 100.0% |
CEO tenure | 8.6yrs |
CEO ownership | 2.7% |
Management average tenure | 2.2yrs |
Board average tenure | 3.7yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -AU$18m |
Mar 31 2024 | n/a | n/a | -AU$17m |
Dec 31 2023 | n/a | n/a | -AU$17m |
Sep 30 2023 | n/a | n/a | -AU$19m |
Jun 30 2023 | AU$354k | AU$354k | -AU$21m |
Mar 31 2023 | n/a | n/a | -AU$22m |
Dec 31 2022 | n/a | n/a | -AU$23m |
Sep 30 2022 | n/a | n/a | -AU$22m |
Jun 30 2022 | AU$629k | AU$422k | -AU$20m |
Mar 31 2022 | n/a | n/a | -AU$19m |
Dec 31 2021 | n/a | n/a | -AU$18m |
Sep 30 2021 | n/a | n/a | -AU$17m |
Jun 30 2021 | AU$481k | AU$281k | -AU$16m |
Dec 31 2020 | n/a | n/a | -AU$13m |
Sep 30 2020 | n/a | n/a | -AU$16m |
Jun 30 2020 | AU$440k | AU$290k | -AU$19m |
Dec 31 2019 | n/a | n/a | -AU$18m |
Sep 30 2019 | n/a | n/a | -AU$14m |
Jun 30 2019 | AU$495k | AU$330k | -AU$11m |
Dec 31 2018 | n/a | n/a | -AU$7m |
Sep 30 2018 | n/a | n/a | -AU$7m |
Jun 30 2018 | AU$498k | AU$334k | -AU$8m |
Compensation vs Market: Roby's total compensation ($USD244.29K) is below average for companies of similar size in the US market ($USD666.26K).
Compensation vs Earnings: Roby's compensation has been consistent with company performance over the past year.
CEO
Roby Zomer (44 yo)
8.6yrs
Tenure
AU$354,018
Compensation
Mr. Roby Reuven Zomer is a Co-Founder of Argent BioPharma Limited (formerly known as MGC Pharmaceuticals Limited) and served as its Interim Chief Financial Officer since April 2022 until April 2022. Mr. Zo...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 8.6yrs | AU$354.02k | 2.67% A$ 307.7k | |
Chief Financial Officer | less than a year | no data | no data | |
Deputy CEO & COO | 1.9yrs | no data | 37.79% A$ 4.4m | |
Chief Accounting Officer | 1.6yrs | no data | no data | |
Global Chief Sales Officer | 3.7yrs | no data | no data | |
Chief Pharmaceutical Development Officer | no data | no data | no data | |
Head of the Quality Assurance Department | 4yrs | no data | no data | |
Chief Medical Officer | no data | no data | no data | |
Deputy CEO | no data | no data | no data | |
Chief Information Security Officer | no data | no data | no data | |
Chief Commercial Officer | 2.2yrs | no data | no data | |
Chief Manufacturing & Supply Chain Officer | no data | no data | no data |
2.2yrs
Average Tenure
Experienced Management: RGTL.F's management team is considered experienced (2.2 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 8.6yrs | AU$354.02k | 2.67% A$ 307.7k | |
Chairman of Strategic Advisory Board | no data | AU$44.00k | 0.010% A$ 1.2k | |
Member of Strategic Advisory Board | 8.2yrs | no data | no data | |
Independent Non-Executive Director | 1.3yrs | no data | no data | |
Member of Medical Advisory Board | 6.2yrs | no data | no data | |
Non-Executive Director | less than a year | no data | no data | |
Member of Advisory Board | less than a year | no data | no data |
3.7yrs
Average Tenure
Experienced Board: RGTL.F's board of directors are considered experienced (3.7 years average tenure).